BIMZELX®?(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... [Yahoo! Finance]
UCB (UCBJY) was upgraded by Wolfe Research to "strong-buy".
Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026
UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for (Pr)BIMZELX® for hidradenitis suppurativa (HS) [Yahoo! Finance]